Merck Stock News

It's a new year and apparently there's a new theme on Wall Street for investors. Many of the Magnificent Seven stocks and their high-flying tech peers are off to a difficult start in 2024.

The Weekly MDA Breakouts completed the best year since this model was released on Seeking Alpha in 2017. In 2023, 125 picks gained over 5% and 65 picks gained over 10% in their measured week, with sim

The Dow is an excellent starting place if you are looking for foundational holdings. However, some Dow stocks would be best for investors to avoid right now.

Merck and Moderna are teaming up to make an advanced oncology drug. The candidate's clinical trials are proceeding swimmingly.

In the most recent trading session, Merck (MRK) closed at $107.98, indicating a +0.33% shift from the previous trading day.

With the possibility of an interest rate cut by the FED and fairly optimistic targets for the S&P 500 index by the largest analytical groups, investors might be looking for the best opportunities in t

Merck remains undervalued with a strong set of growing drugs and new indications in its pipeline. Keytruda has been a major revenue driver for MRK, with continued sales growth and potential for extend

Merck has managed to thrive throughout its 132-year corporate history. The company posted healthy sales and non-GAAP EPS growth in the third quarter. Merck boasts an A+ credit rating from S&P on a sta

Merck & Co. is a drug manufacturer that has outperformed the healthcare ETF and the S&P 500 over the past decade. The company's pharmaceutical segment, including products like Keytruda and vaccines, c

As the world bids adieu to one year and eagerly ushers in the next, the financial landscape comes alive with whispers of a phenomenon known as the January Effect. It's a time when astute investors set

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often

With the Federal Reserve seemingly open to the idea of interest rate cuts next year, the narrative for the best Dow Jones stocks for conservative investors appears overly cautious. Don't get me wrong

The U.S. Food and Drug Administration (FDA) has declined to approve Merck's drug for chronic cough, the company said on Wednesday, marking the second rejection in less than two years.

Jared Holz, Mizuho healthcare sector specialist, joins 'The Exchange' to discuss the 2024 outlook for health care, which stocks to buy in the new year, and more.

Consider These 3 SWAN Stocks To Collect Dividends Almost Monthly